View ValuationHydration Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Hydration Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長13.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.Board Change • Mar 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (AU$2.15m market cap, or US$1.53m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.お知らせ • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights OfferingNew Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$4.68m market cap, or US$3.06m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).Board Change • Apr 12High number of new directorsNon-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025.Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).New Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$3.70m market cap, or US$2.31m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).お知らせ • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offeringお知らせ • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).分析記事 • Jun 25Take Care Before Jumping Onto The Hydration Pharmaceuticals Company Limited (ASX:HPC) Even Though It's 31% CheaperUnfortunately for some shareholders, the The Hydration Pharmaceuticals Company Limited ( ASX:HPC ) share price has...Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.分析記事 • May 02Sentiment Still Eluding The Hydration Pharmaceuticals Company Limited (ASX:HPC)The Hydration Pharmaceuticals Company Limited's ( ASX:HPC ) price-to-sales (or "P/S") ratio of 0.3x might make it look...Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).お知らせ • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.New Risk • Oct 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (AU$9.53m market cap, or US$6.06m).New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).Reported Earnings • Sep 04First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).お知らせ • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).お知らせ • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.お知らせ • Dec 03The Hydration Pharmaceuticals Company Limited Launches Co-Branded ProductThe Hydration Pharmaceuticals Company Limited advised it has successfully launched its co-branded stockkeeping unit (SKU) alongside brand ambassador and entrepreneur, Ms. Shay Mitchell. The new product is being sold through Hydralyte North America's ecommerce channels, as well as Amazon USA. RiteAid, a major US retailer, will stock the product in the coming weeks, while additional ranging across additional retail outlets will occur in the coming weeks. The initial launch through online channels provides Hydralyte North America with the opportunity to leverage its established customer base, which has grown considerably in the past 12 months. Amazon US sales rose 62% on the prior corresponding period during Third Quarter FY2022, with customer subscriptions increasing 5% to 12% per month during FY2022. Ms. Mitchell's co-branded SKU has been launched in two sizes; a six-stick box designed for traditional retail outlets, as well as a larger 18 stick value pack for more convenient and higher margin sales across ecommerce channels (refer images overleaf). The launch follows an extensive period of production development in direct collaboration with Ms. Mitchell, which involved flavour testing, packaging design, manufacturing, and consultation on online and in-person marketing strategies. The launch will be complemented by a two-day marketing event, hosted by Ms Mitchell in Florida. The marketing installation is positioned to bring together 16 of America's top influencers, each of which have large individual social media follower bases and has the potential to deliver considerable value from social media posts and brand awareness. The one-off costs associated with the event have already been realised by the Company. It is expected that Ms. Mitchell will also be able to leverage her established social media presence to boost awareness of the new product launch. As a gauge of Ms. Mitchell's popularity in the Company's core target markets, her social media presence currently stands at 34.9m Instagram followers, 2.9m Twitter followers, 4.18m YouTube subscribers and 7.3m followers on TikTok.お知らせ • Dec 02Shay Mitchell Debuts New Lemon Squeeze Flavor Rapid Hydration Drink in Collaboration with HydraLyteHydraLyte announced that Shay Mitchell, actress, producer and entrepreneur, announced her collaboration with HydraLyte to launch her new flavor, Lemon Squeeze. Since the announcement of their partnership in May of 2022, Mitchell has led the co-development process to create a rejuvenating hydration option for the entire family. Throughout the process, Mitchell assumed an elevated role as an investor and part owner in the company, personally testing 12 variations of the product to find the perfect flavor balance. Beyond just perfecting a delicious flavor, Mitchell remained closely involved in the journey, spearheading execution details such as packaging, marketing strategy, and creative. This citrusy electrolyte mix is sized to serve in 16-ounces of water and is proven to be effective in preventing and relieving mild to moderate dehydration. Trusted by the medical community, professional athletes and families around the world, HydraLyte's products are acclaimed for their all-natural formula scientifically developed with: Almost half the sugar of leading electrolyte drink brands; Clean, vegan, non-GMO ingredients; No artificial colors, flavors or sweeteners, gluten, dairy, or caffeine; and A ratio of glucose and electrolytes that activates rapid rehydration faster than water alone. HydraLyte x Shay Mitchell Lemon Squeeze flavor will be available for $24.99 on the HydraLyte website and Amazon on November 30, 2022 with more retailers to come in the new year.お知らせ • Nov 16Hydration Pharmaceuticals Company Limited Secures Key Regulatory Approval for Product Manufacturing for the Canadian MarketThe Hydration Pharmaceuticals Company Limited confirm it has secured key regulatory approval for product manufacturing for the Canadian market. The Company advises that it has formally received manufacturing approval from Health Canada - a key regulatory update which allows Hydralyte North America's US-based contract manufacturer to commence production of the Company's liquid range for the Canadian market. The Health Canada approval was viewed by the management team as a strategic priority which allows the Company to optimise its manufacturing processes from a centralised production hub, and capitalise on its existing distribution channels across the North American market. Hydralyte North America currently sells four stock keeping units (SKU) under its ready-to-drink range which are stocked by major Canadian retail outlets, including Shoppers Drug Mart and a large number of independent stores. Securing Health Canada approval for manufacturing in the US is expected to lead to a reduction in cost of goods sold, cheaper freights and potentially underpin an increase in gross margins for the Company's liquid SKUs.Reported Earnings • Aug 31First half 2022 earnings released: US$0.03 loss per share (vs US$0.039 loss in 1H 2021)First half 2022 results: US$0.03 loss per share. Revenue: US$4.13m (up 80% from 1H 2021). Net loss: US$4.24m (loss widened 92% from 1H 2021).Reported Earnings • Apr 06Full year 2021 earnings released: US$0.12 loss per share (vs US$0.011 loss in FY 2020)Full year 2021 results: US$0.12 loss per share (down from US$0.011 loss in FY 2020). Revenue: US$6.13m (up 63% from FY 2020). Net loss: US$8.95m (loss widened US$8.21m from FY 2020).お知らせ • Mar 31The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022.分析記事 • Mar 15Is Hydration Pharmaceuticals (ASX:HPC) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Mar 01Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$5.92m (up 57% from FY 2020). Net loss: US$8.97m (loss widened US$8.22m from FY 2020). Revenue was in line with analyst estimates.お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Management AppointmentsThe Hydration Pharmaceuticals Company Limited announced it has appointed experienced US business executive Margaret Hardin to its Board as an Independent Non-Executive Director. Ms. Hardin is a global products senior executive and board director, who has previously scaled two consumer goods companies to generate more than USD100 million in revenue, and currently advises founders on growth opportunities. As CEO of ERGObaby Carrier Inc. from 2013 to 2020, Ms Hardin revived product innovation while managing an omni-channel distributor, retail and eCommerce model across more than 60 countries and 19 company-owned websites. In addition, Vanessa Dew, an entrepreneur and investor from Los Angeles, has joined Hydralyte North America's advisory team. Ms. Dew is the co-founder and Chief Sales Officer of Health-Ade, one of the largest kombucha brands in the USA. Concurrently, she has worked with several emerging, innovative brands as a board member and advisor.Board Change • Dec 31High number of new directorsIndependent Non-Executive Chairman George Livery was the last director to join the board, commencing their role in 2021.お知らせ • Dec 11The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million.The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 58,620,690 Price\Range: AUD 0.29 Discount Per Security: AUD 0.01595 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Hydration Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:HPC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-3-4-4N/A9/30/20253-4-4-4N/A6/30/20253-5-3-3N/A3/31/20253-5-4-4N/A12/31/20243-6-4-4N/A6/30/20241-6-5-5N/A3/31/20243-7-5-5N/A12/31/20234-7-6-6N/A9/30/202310-9-7-7N/A6/30/202310-10-8-8N/A3/31/202310-10-9-9N/A12/31/20229-11-10-10N/A9/30/20229-11-9-9N/A6/30/20228-11-9-9N/A3/31/20227-10-9-9N/A12/31/20216-9-8-8N/A9/30/20215-6-7-7N/A6/30/20214-4-5-5N/A3/31/20214-2-3-4N/A12/31/20204-1-1-4N/A12/31/20193-3-3-3N/A12/31/20184-10N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HPCの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: HPCの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: HPCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: HPCの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: HPCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 05:47終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋The Hydration Pharmaceuticals Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 30The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026.
Board Change • Mar 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.7m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (AU$2.15m market cap, or US$1.53m). Minor Risk Revenue is less than US$5m (US$2.5m revenue).
Reported Earnings • Mar 02Full year 2025 earnings released: US$0.71 loss per share (vs US$0.02 loss in FY 2024)Full year 2025 results: US$0.71 loss per share. Revenue: US$2.47m (down 23% from FY 2024). Net loss: US$2.75m (loss narrowed 52% from FY 2024).
Reported Earnings • Aug 31First half 2025 earnings released: US$0.004 loss per share (vs US$0.011 loss in 1H 2024)First half 2025 results: US$0.004 loss per share (improved from US$0.011 loss in 1H 2024). Revenue: US$1.53m (down 69% from 1H 2024). Net loss: US$1.33m (loss narrowed 57% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
お知らせ • Jul 10The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,387,853 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 39,500,000 Price\Range: AUD 0.01 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: AUD 0.01 Transaction Features: Rights Offering
New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$4.68m market cap, or US$3.06m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).
Board Change • Apr 12High number of new directorsNon-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025.
Reported Earnings • Apr 05Full year 2024 earnings released: US$0.02 loss per share (vs US$0.037 loss in FY 2023)Full year 2024 results: US$0.02 loss per share (improved from US$0.037 loss in FY 2023). Revenue: US$3.20m (down 26% from FY 2023). Net loss: US$5.67m (loss narrowed 22% from FY 2023).
New Risk • Apr 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Market cap is less than US$10m (AU$3.70m market cap, or US$2.31m). Minor Risk Revenue is less than US$5m (US$3.2m revenue).
お知らせ • Mar 25The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 18+ 1 more updateThe Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million.The Hydration Pharmaceuticals Company Limited has filed a Follow-on Equity Offering in the amount of AUD 0.609826 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,982,614 Price\Range: AUD 0.01 Transaction Features: Rights Offering
お知らせ • Mar 14The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025.
Reported Earnings • Mar 01Full year 2024 earnings released: US$0.021 loss per share (vs US$0.042 loss in FY 2023)Full year 2024 results: US$0.021 loss per share (improved from US$0.042 loss in FY 2023). Revenue: US$3.20m (down 68% from FY 2023). Net loss: US$5.67m (loss narrowed 30% from FY 2023).
分析記事 • Jun 25Take Care Before Jumping Onto The Hydration Pharmaceuticals Company Limited (ASX:HPC) Even Though It's 31% CheaperUnfortunately for some shareholders, the The Hydration Pharmaceuticals Company Limited ( ASX:HPC ) share price has...
Board Change • May 29Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 24The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.
分析記事 • May 02Sentiment Still Eluding The Hydration Pharmaceuticals Company Limited (ASX:HPC)The Hydration Pharmaceuticals Company Limited's ( ASX:HPC ) price-to-sales (or "P/S") ratio of 0.3x might make it look...
Reported Earnings • Apr 03Full year 2023 earnings released: US$0.042 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.042 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
Reported Earnings • Mar 01Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022)Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022).
お知らせ • Feb 22The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024.
New Risk • Oct 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (AU$9.53m market cap, or US$6.06m).
New Risk • Sep 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
Reported Earnings • Sep 04First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022)First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022).
お知らせ • Aug 29The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September.
New Risk • Aug 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding).
お知らせ • Aug 12The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 33,333,337 Price\Range: AUD 0.045 Discount Per Security: AUD 0.0027 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Mar 01Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021)Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021).
お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Executive ChangesThe Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.
お知らせ • Dec 03The Hydration Pharmaceuticals Company Limited Launches Co-Branded ProductThe Hydration Pharmaceuticals Company Limited advised it has successfully launched its co-branded stockkeeping unit (SKU) alongside brand ambassador and entrepreneur, Ms. Shay Mitchell. The new product is being sold through Hydralyte North America's ecommerce channels, as well as Amazon USA. RiteAid, a major US retailer, will stock the product in the coming weeks, while additional ranging across additional retail outlets will occur in the coming weeks. The initial launch through online channels provides Hydralyte North America with the opportunity to leverage its established customer base, which has grown considerably in the past 12 months. Amazon US sales rose 62% on the prior corresponding period during Third Quarter FY2022, with customer subscriptions increasing 5% to 12% per month during FY2022. Ms. Mitchell's co-branded SKU has been launched in two sizes; a six-stick box designed for traditional retail outlets, as well as a larger 18 stick value pack for more convenient and higher margin sales across ecommerce channels (refer images overleaf). The launch follows an extensive period of production development in direct collaboration with Ms. Mitchell, which involved flavour testing, packaging design, manufacturing, and consultation on online and in-person marketing strategies. The launch will be complemented by a two-day marketing event, hosted by Ms Mitchell in Florida. The marketing installation is positioned to bring together 16 of America's top influencers, each of which have large individual social media follower bases and has the potential to deliver considerable value from social media posts and brand awareness. The one-off costs associated with the event have already been realised by the Company. It is expected that Ms. Mitchell will also be able to leverage her established social media presence to boost awareness of the new product launch. As a gauge of Ms. Mitchell's popularity in the Company's core target markets, her social media presence currently stands at 34.9m Instagram followers, 2.9m Twitter followers, 4.18m YouTube subscribers and 7.3m followers on TikTok.
お知らせ • Dec 02Shay Mitchell Debuts New Lemon Squeeze Flavor Rapid Hydration Drink in Collaboration with HydraLyteHydraLyte announced that Shay Mitchell, actress, producer and entrepreneur, announced her collaboration with HydraLyte to launch her new flavor, Lemon Squeeze. Since the announcement of their partnership in May of 2022, Mitchell has led the co-development process to create a rejuvenating hydration option for the entire family. Throughout the process, Mitchell assumed an elevated role as an investor and part owner in the company, personally testing 12 variations of the product to find the perfect flavor balance. Beyond just perfecting a delicious flavor, Mitchell remained closely involved in the journey, spearheading execution details such as packaging, marketing strategy, and creative. This citrusy electrolyte mix is sized to serve in 16-ounces of water and is proven to be effective in preventing and relieving mild to moderate dehydration. Trusted by the medical community, professional athletes and families around the world, HydraLyte's products are acclaimed for their all-natural formula scientifically developed with: Almost half the sugar of leading electrolyte drink brands; Clean, vegan, non-GMO ingredients; No artificial colors, flavors or sweeteners, gluten, dairy, or caffeine; and A ratio of glucose and electrolytes that activates rapid rehydration faster than water alone. HydraLyte x Shay Mitchell Lemon Squeeze flavor will be available for $24.99 on the HydraLyte website and Amazon on November 30, 2022 with more retailers to come in the new year.
お知らせ • Nov 16Hydration Pharmaceuticals Company Limited Secures Key Regulatory Approval for Product Manufacturing for the Canadian MarketThe Hydration Pharmaceuticals Company Limited confirm it has secured key regulatory approval for product manufacturing for the Canadian market. The Company advises that it has formally received manufacturing approval from Health Canada - a key regulatory update which allows Hydralyte North America's US-based contract manufacturer to commence production of the Company's liquid range for the Canadian market. The Health Canada approval was viewed by the management team as a strategic priority which allows the Company to optimise its manufacturing processes from a centralised production hub, and capitalise on its existing distribution channels across the North American market. Hydralyte North America currently sells four stock keeping units (SKU) under its ready-to-drink range which are stocked by major Canadian retail outlets, including Shoppers Drug Mart and a large number of independent stores. Securing Health Canada approval for manufacturing in the US is expected to lead to a reduction in cost of goods sold, cheaper freights and potentially underpin an increase in gross margins for the Company's liquid SKUs.
Reported Earnings • Aug 31First half 2022 earnings released: US$0.03 loss per share (vs US$0.039 loss in 1H 2021)First half 2022 results: US$0.03 loss per share. Revenue: US$4.13m (up 80% from 1H 2021). Net loss: US$4.24m (loss widened 92% from 1H 2021).
Reported Earnings • Apr 06Full year 2021 earnings released: US$0.12 loss per share (vs US$0.011 loss in FY 2020)Full year 2021 results: US$0.12 loss per share (down from US$0.011 loss in FY 2020). Revenue: US$6.13m (up 63% from FY 2020). Net loss: US$8.95m (loss widened US$8.21m from FY 2020).
お知らせ • Mar 31The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 27, 2022.
分析記事 • Mar 15Is Hydration Pharmaceuticals (ASX:HPC) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Mar 01Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$5.92m (up 57% from FY 2020). Net loss: US$8.97m (loss widened US$8.22m from FY 2020). Revenue was in line with analyst estimates.
お知らせ • Feb 08The Hydration Pharmaceuticals Company Limited Announces Management AppointmentsThe Hydration Pharmaceuticals Company Limited announced it has appointed experienced US business executive Margaret Hardin to its Board as an Independent Non-Executive Director. Ms. Hardin is a global products senior executive and board director, who has previously scaled two consumer goods companies to generate more than USD100 million in revenue, and currently advises founders on growth opportunities. As CEO of ERGObaby Carrier Inc. from 2013 to 2020, Ms Hardin revived product innovation while managing an omni-channel distributor, retail and eCommerce model across more than 60 countries and 19 company-owned websites. In addition, Vanessa Dew, an entrepreneur and investor from Los Angeles, has joined Hydralyte North America's advisory team. Ms. Dew is the co-founder and Chief Sales Officer of Health-Ade, one of the largest kombucha brands in the USA. Concurrently, she has worked with several emerging, innovative brands as a board member and advisor.
Board Change • Dec 31High number of new directorsIndependent Non-Executive Chairman George Livery was the last director to join the board, commencing their role in 2021.
お知らせ • Dec 11The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million.The Hydration Pharmaceuticals Company Limited has completed an IPO in the amount of AUD 17 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 58,620,690 Price\Range: AUD 0.29 Discount Per Security: AUD 0.01595